Four specific substances classified as monoclonal antibodies– Bamlanivimab, Etesevimab, Leronlimab and REGN-COV2—have new PCS codes to track their use in treating COVID-19. Leronlimab is administered by subcutaneous injection, and the other three substances are administered via IV infusion.


XW013K6 Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6